(ShareCast News) - The chief executive of Allergy Therapeutics bought new shares in the company few days after releasing a positive trading update.Manuel Llobet purchased 50,000 shares for an individual price of 24.45p, spending a total of £12,225.After the transaction, Llobet holds 3.175m shares in the pharmaceutical group.The company said on Thursday it expects to report a 11% increase in revenues for the full-year ended 30 June 2015.The chief executive said at the time the welcoming of its short course aluminium free therapies in Europe and the compliance of its Pollinex Quattro franchise, gave the group "great encouragement" for Pollinex Quattro's success in the US market when launched in 2019.He also said the acquisition of Alerpharma is a "compelling illustration of the company executing its strategy in Europe".Top Director BuysLowland Investment Co (LWI) Director name: Dr Kevin CarterAmount purchased: 3,000 @ 1,373.60p Value: £41,208Allergy Therapeutics (AGY) Director name: Mr Manuel Llobet Amount purchased: 50,000 @ 24.45p Value: £12,225Top Director SellsThere were so sells today.